Evaluation of ANIF1 antiviral drug in COVID-19 patients: A Randomized Clinical Trial

Evaluation of clinical and laboratory effect of ANIF1 new antiviral drug in COVID-19 patients

Clinical trial, double blind, with control group, randomized.patients and docters dont know about which group they are ,drug and placebo,.an accidental tabale number use to decrese the bias

Eligible patients are selected and introduced to the nurse to deliver the drug package,.afterrandomizatin The package includes one syrup in two types of antiviral drug with placebo tablets and another syrup of multivitamins and chloroquine. Blood samples and nasal swabs will be taken for testing.

Patients suspected of having coronavirus will enter the initial screening with the initial symptoms of fever, cough, shortness of breath, myalgia, weakness, or gastrointestinal symptoms. In case of lymphopenia less than 1100, patients will be sent for RT-PCR test to confirm the disease, as well as patients in the CT scan of the lungs who have been diagnosed with a definite case of coronavirus and are between 18 and 65 years old will entered to the study. Also patients 1- Fever above 38 degrees 2- Lymphocytes count less than 101 3- Positive CRP 4- Positive respiratory symptoms (cough or shortness of breath or tachypnea or ...) 5- Symptoms of pulmonary involvement in lung or CT scan will enter the study will be entered to the study we exclude end organ disease and severe imunnocompromised patients

In 30 subjects, the ANIF1-tested group will receive 10 cc of oral syrup three twice a day for7days at specific doses. The control group will be 30 patients who will receive the standard medication regimen as recommended by the national standard protocol.(HCQ200BID and/or kaletra400mg bid)+ SYRUP MULTIVITAMIN as placebo

RT-PCR and CT scan of the lungs, level of inflammatory biomarkers

patients will be assigned one in between and randomly into two groups with accidental code

Patients will receive same taste and smell syrups, one with ANIF1 and other with multivitamin and chloroquine. Eligible patients are selected and introduced to the nurse to deliver the drug package, and the nurse gives one of the packages, respectively. The package includes one syrup in two. It is an antiviral drug with placebo tablets and another multivitamin and chloroquine syrup. Patients and researchers are unaware of the contents of the package.

Data will be Released after the article is published

after study conduction

health care workers

for further investigation and therapeutic uses

Person in charge for study

official letter